Clearmind Medicine Completes Treatment for 18 Participants in Alcohol Use Disorder Trial

Key Facts

1Clearmind Medicine completed treatment and follow-up for 18 participants in its Phase I/IIa clinical trial of CMND-100.

2CMND-100 is a non-hallucinogenic MEAI-based oral drug candidate targeting Alcohol Use Disorder (AUD).

3The trial is FDA-approved and conducted across multiple international sites to evaluate safety and preliminary efficacy.

Clearmind Medicine Inc. (Nasdaq: CMND) has announced the successful completion of treatment and follow-up for 18 participants in its Phase I/IIa clinical trial. The trial evaluates CMND-100, a non-hallucinogenic oral drug candidate designed to treat Alcohol Use Disorder (AUD). The study is conducted across multiple international sites under an FDA-approved protocol to assess the safety and preliminary efficacy of the MEAI-based compound. This milestone represents a significant step forward in the company's efforts to develop neuroplastogen-derived therapeutics for major under-treated health conditions. Clinical progress in such trials is often viewed as a positive catalyst for biotechnology firms, as it demonstrates operational progress and reduces execution risk. Clearmind continues to focus on advancing its clinical pipeline to address the global challenge of alcohol addiction through innovative medical solutions.